XOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLC

Stonepine Capital Management LLC reduced its position in shares of XOMA Co. (NASDAQ:XOMA) by 22.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 195,096 shares of the biotechnology company’s stock after selling 55,033 shares during the period. XOMA comprises approximately 3.3% of Stonepine Capital Management LLC’s holdings, making the stock its 6th largest holding. Stonepine Capital Management LLC owned about 1.66% of XOMA worth $5,166,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in XOMA during the first quarter worth about $212,000. Rhumbline Advisers lifted its holdings in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares during the last quarter. Ellsworth Advisors LLC acquired a new position in XOMA in the third quarter valued at approximately $516,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.20% of the stock is currently owned by insiders.

XOMA Stock Performance

XOMA stock traded up $0.50 on Wednesday, reaching $34.38. The company’s stock had a trading volume of 3,380 shares, compared to its average volume of 22,115. XOMA Co. has a 52 week low of $14.33 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a market capitalization of $405.00 million, a P/E ratio of -9.74 and a beta of 0.90. The firm has a fifty day moving average of $29.11 and a two-hundred day moving average of $27.20.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on XOMA. HC Wainwright reissued a “buy” rating and issued a $117.00 price target on shares of XOMA in a report on Wednesday, October 23rd. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

XOMA Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.